Combination of Ranibizumab and Targeted Laser Photocoagulation
Ключови думи
Резюме
Описание
Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina and/or the anterior segment is the most serious complication leading to vitreous hemorrhage, retinal detachment and neovascular glaucoma. In serious cases loss of vision is imminent. To date, no causal treatment has been proven to be effective in large trials. Intravitreal injections of drugs that inhibit the vascular endothelial growth factor (VEGF) and other inflammatory factors are the current treatments of choice for ME due to CRVO. Two different anti-VEGF drugs (ranibizumab and aflibercept), and a biodegradable dexamethasone implant are approved by the EMA (European Medicines Agency). Based on data from confirmatory studies anti-VEGF-drugs are recommended as a treatment of first choice in patients with RVO. All intravitreal drugs provide only a temporary effect with need for re-treatment for recurrences of ME. Mean number of ranibizumab application needed in CRVO patients was found to be 7.4 to 10.2 injections in 12 months. A significant number of CRVO patients require treatment over several years. Need for repetitive treatments and ophthalmic controls are a major burden for patients (and their relatives who are required for driving the patients to ophthalmologists) despite of only few adverse events and generally well-tolerated injections. Endophthalmitis is the most severe ocular complication which can be eye-sight-threatening. The more injections are administered, the higher is the cumulative risk of complications. Due to high costs (>1000 € per injection) treatment with repeated injections over years is of significant socio-economic importance, too. Therefore, treatments concepts which would lead to permanent reduction of ME and/or significantly reduce the number of re-injections over long-term periods are the major currently unmet need in patients with RVO.
Until now, several studies evaluated the impact of the additional pan-retinal laser photocoagulation in patients undergoing the anti-VEGF-treatment for the ME due to retinal vein occlusions. However, most of the studies are limited by retrospective design, small number of evaluated patients or lack of the randomization. None of the available prospective randomized studies had sufficient power to finally clarify the benefit of the additional laser treatment. Therefore, there is an unmet need for a large randomized, prospective, multicentric trials.
The proposed study will be the first sufficiently powered trial evaluating the long-term effect of targeted laser photocoagulation performed selectively (targeted) in peripheral areas of non-perfusion in combination with standard anti-VEGF treatment (ranibizumab injections) on the duration of the required intravitreal treatment over time period of 2 years.
Дати
| Последна проверка: | 05/31/2020 |
| Първо изпратено: | 06/18/2020 |
| Очаквано записване подадено: | 06/21/2020 |
| Първо публикувано: | 06/22/2020 |
| Изпратена последна актуализация: | 07/21/2020 |
| Последна актуализация публикувана: | 07/23/2020 |
| Действителна начална дата на проучването: | 07/31/2020 |
| Приблизителна дата на първично завършване: | 07/29/2024 |
| Очаквана дата на завършване на проучването: | 07/29/2024 |
Състояние или заболяване
Интервенция / лечение
Drug: Ranibizumab Injection
Device: Ranibizumab+Laser-arm
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Ranibizumab+Laser-arm Ranibizumab injections and additional targeted laser | Device: Ranibizumab+Laser-arm Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times |
| Active Comparator: Ranibizumab-arm Only Ranibizumab injections |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Diagnosis of macular edema due to central retinal vein occlusion foveal thickness > 250 μm (measured by OCT) - Age > 18 years - Written informed consent of the patient - BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25) measured in ETDRS chart - History of CRVO no longer than 6 months - Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas documented in ultra wide-field fluorescein angiography - Ability and willingness to attend all scheduled visits and assessments Exclusion Criteria: - CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone larger than 2 optic disc diameters - Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome) - History of idiopathic central serous chorioretinopathy - Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal membrane), either on clinical examination or in OCT - An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates - Aphakia in the study eye - Scatter laser photocoagulation or macular photocoagulation in the study eye prior to study entry - Intraocular or periocular injection of steroids in the study eye prior to study entry - Previous use of an anti-VEGF drug in the study eye - Cataract surgery or any other intraocular surgery in the study eye within 3 months prior to study entry - Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm Hg despite treatment with maximal anti-glaucoma medications) - History of stroke, myocardial infarction, transient ischemic attacks within 3 months prior to the study - Pregnancy (positive urine pregnancy test) or lactation - The presence of active malignancy, including lymphoproliferative disorders. - History of allergy to fluorescein or any component of the ranibizumab formulation - Active intraocular infection - Participation in another simultaneous interventional medical investigation or trial - Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial. |
Резултат
Първични изходни мерки
1. Efficacy endpoint is the time to treatment success [up-to 29 months]
Вторични изходни мерки
1. Best corrected visual acuity (BCVA) [Month 29]
2. Central subfield thickness (CST) [Month 29]
3. Number of ranibizumab injections [Month 29]
Други изходни мерки
1. Development of neovascularization(s) [Month 24]
2. The area of non-perfusion [Month 24]
3. Vessel density [Month 24]
4. Potential visual field loss [Month 4 and Month 24]
5. The number of laser treatments and the laser spots given in the experimental group (RL-arm). [Month 24]
6. Health-related quality of life (QoL): Visual Function Questionnaire VFQ25 [Baseline, Month 12 and Month 24]
7. Areal of foveal avascular zone [Month 24]
